학술논문

Anal incontinence after obstetrical anal sphincter injury significantly impacts quality of life for women: a cohort study.
Document Type
Article
Source
Langenbeck's Archives of Surgery. 2/17/2024, Vol. 409 Issue 1, p1-9. 9p.
Subject
*ANUS
*INFLAMMATORY bowel diseases
*QUALITY of life
*FECAL incontinence
*COHORT analysis
Language
ISSN
1435-2443
Abstract
Purpose: To assess the prevalence of anal incontinence (AI) after obstetrical anal sphincter injuries (OASIS) and its severity, as well as the risk factors for AI and AI episodes ≥ 6 months. Methods: This prospective and observational monocentric cohort study included all the women who had an OASIS between 1 January 2005 and 31 December 2019. Information was collected by using a letter informing for the fecal incontinence quality of life (FIQL) questionnaire and by a phone interview. The main outcome measure was "1 passed or ongoing episode of AI". Results: Among the 227 patients included, 19.8% had ongoing AI, and 35.2% had AI passed or ongoing episodes. A total of 46.7% of women with AI reported a change in their quality of life in all fields of the FIQL. Excluding a history of inflammatory bowel disease, no factor was associated with the incidence of an AI episode. Post-obstetrical AI ≥ 6 months (POAI ≥ 6) represented 63.7% of AI cases. This incontinence began with significant incidence in the immediate postpartum period but increased over time, unlike AI < 6 months, which appeared primarily in the immediate postpartum period. Instrumental birth was a protective factor for POAI ≥ 6 (OR = 0.24; CI 95% [0.08–0.78]; p = 0.016), while an increase in parity and BMI were risk factors for POAI ≥ 6 (OR = 4.21; CI 95% [1.01–17.71]; p = 0.05 and OR = 1.15; CI 95% [1.03–1.30]; p = 0.016, respectively). Conclusion: The prevalence of AI after OASIS is not underestimated. Despite the fact that women do not seek care, the impact of AI on the quality of life is significant. A case of AI that lasts for 6 months after giving birth risks becoming chronic. Therefore, specialist advice should be recommended in this case. Clinical trial registry: NCT04940494. [ABSTRACT FROM AUTHOR]